SLC5A2 and diabetic kidney disease: The inclusion of other antidiabetic agents, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, could have provided a more comprehensive understanding of the effects of different treatments on sCD36 and DKD progression.5, Potential Confounding Factors: Although adjustments were made for key variables, unmeasured confounding factors such as dietary patterns and physical activity may have influenced the outcomes.6, It is important to acknowledge that this study utilized a non-randomized, observational cohort design, which introduces potential selection bias.